Chemomab Therapeutics Ltd. (CMMB): Cash & Equivalents
$7.56M
As of 2025-12-31
-17.6%
3-year compound annual growth
-8.3%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.56M | +24.6% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $6.07M | -34.7% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $9.29M | -31.3% | 2025-04-04, Balance as of period end |
| 2022-12-31 | $13.52M | -11.0% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $15.19M | +30.1% | 2023-03-20, Balance as of period end |
| 2020-12-31 | $11.67M | -33.6% | 2022-03-30, Balance as of period end |
| 2019-12-31 | $17.57M | +133.8% | 2021-03-09, Balance as of period end |
| 2018-12-31 | $7.52M | n/a | 2020-03-17, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Chemomab Therapeutics Ltd. (CMMB) | 2025-12-31 | $7.56M | +24.6% |
| CytoDyn Inc. (CYDY) | 2026-05-31 | $11.85M | -0.4% |
| Actuate Therapeutics, Inc. (ACTU) | 2025-12-31 | $13.16M | +52.3% |
| CalciMedica, Inc. (CALC) | 2025-12-31 | $11.52M | +45.2% |
| Edesa Biotech, Inc. (EDSA) | 2025-09-30 | $10.80M | +980.0% |
| Biovie Inc. (BIVI) | 2026-06-30 | $8.98M | -48.8% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $7.80M | +440.3% |
| PMGC Holdings Inc. (ELAB) | 2024-12-31 | $3.98M | +19.8% |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $13.20M | -43.3% |
Compare CMMB, CYDY, ACTU, CALC side by side · Screen every company in Pharmaceutical Preparations ↗